Celebrating Black History Month in the ophthalmic community
February 26th 2016While there is still a long way to go for better representation in ophthalmology and medicine in general, let’s take a look at some of the pioneers and achievements of the African American ophthalmic community up until now.
IOL centration stable 30 days after implantation, study confirms
February 19th 2016Ophthalmologists spend significant amounts of time during cataract surgery trying to precisely center an implanted IOL to achieve the best possible vision after surgery. The high success rate of cataract surgery suggests that in most cases, they succeed.
Better alternatives to standalone prostaglandin analog therapy
February 16th 2016Physicians have the option of various adjunctive therapy when prostaglandin analog therapy alone is not sufficiently potent to lower IOP, i.e., they can add one agent, a fixed-combination therapy, or perform selective laser trabeculoplasty (SLT).
Impressive IOP results from second-generation microinvasive surgery
February 15th 2016Implantation of two second-generation trabecular micro-bypass stents (iStent inject, Glaukos) as a single procedure or combined with cataract surgery is a safe and effective option for reducing IOP and the medication burden in eyes with open-angle glaucoma and IOP uncontrolled by medication and/or surgery, according to German surgeons.
The AAO's preferred practice patterns for AMD
February 15th 2016High-level evidence supports the use of anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (AMD), but falls short of recommending any one agent over another in terms of efficacy or safety, said Paul Sternberg Jr., MD.
Surgical gene therapy study for wet AMD yields mixed results
February 15th 2016In a phase IIa study of patients with neovascular age-related macular degeneration, a single subretinal injection of rAAV.sFlt-1 gene therapy demonstrated acceptable safety, but not a complete or durable anti-VEGF response. Additional preclinical research is under way.